Benedict Financial Advisors Inc. Has $9.81 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Benedict Financial Advisors Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 62,566 shares of the company’s stock after acquiring an additional 297 shares during the period. Johnson & Johnson makes up approximately 2.7% of Benedict Financial Advisors Inc.’s holdings, making the stock its 3rd biggest position. Benedict Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $9,807,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Norges Bank purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $4,609,399,000. Charles Schwab Investment Management Inc. grew its stake in shares of Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the period. Finally, Barclays PLC raised its stake in Johnson & Johnson by 61.0% during the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after acquiring an additional 4,278,512 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley dropped their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Raymond James increased their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Royal Bank of Canada reduced their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.36.

Johnson & Johnson Stock Up 0.2 %

Shares of JNJ opened at $144.77 on Thursday. Johnson & Johnson has a 52-week low of $143.39 and a 52-week high of $175.97. The company has a market cap of $348.86 billion, a PE ratio of 10.48, a P/E/G ratio of 2.45 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average of $156.54 and a 200 day moving average of $155.74.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business earned $2.68 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.